% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Ritter:203298,
      author       = {Ritter, Christian and Bobylev, Ilja and Lehmann, Helmar C.},
      title        = {{C}hronic inflammatory demyelinating polyneuropathy
                      ({CIDP}): change of serum {I}g{G} dimer levels during
                      treatment with intravenous immunoglobulins},
      journal      = {Journal of neuroinflammation},
      volume       = {12},
      number       = {1},
      issn         = {1742-2094},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {FZJ-2015-05272},
      pages        = {148},
      year         = {2015},
      abstract     = {BackgroundIntravenous immunoglobulin (IVIg) is an effective
                      treatment in chronic inflammatory demyelinating
                      polyneuropathy (CIDP). In most patients, the optimal IVIg
                      dose and regime is unknown. Polyvalent immunoglobulin (Ig) G
                      form idiotypic/anti-idiotypic antibody pairs in serum and
                      IVIg preparations. We determined IgG dimer levels before and
                      after IVIg treatment in CIDP patients with the aim to
                      explore their utility to serve as a surrogate marker for
                      treatment response.MethodsIgG was purified from serum of
                      five controls without treatment, as well as from serum of 16
                      CIDP patients, two patients with Miller Fisher syndrome
                      (MFS), and one patient with myasthenia gravis before and
                      after treatment with IVIg. IgG dimer levels were determined
                      by size exclusion chromatography. IgG dimer formation was
                      correlated with clinical response to IVIg treatment in CIDP.
                      Re-monomerized IgG dimer fractions were analyzed for
                      immunoreactivity against peripheral nerve tissue.ResultsIgG
                      dimer levels were significantly higher in post- compared to
                      pre-IVIg infusion samples. Low post-treatment IgG dimer
                      levels in CIDP patients were associated with clinical
                      worsening during IVIg treatment. Re-monomerized IgG dimer
                      fractions from CIDP patients showed immunoreactivity against
                      peripheral nerve tissue, whereas similarly treated samples
                      from MFS patients showed immunoreactivity against
                      GQ1b.ConclusionAssessment of IgG dimer levels could be a
                      novel approach to monitor CIDP patients during IVIg
                      treatment, but further studies in larger cohorts are
                      warranted to explore their utility to serve as a potential
                      therapeutic biomarker for IVIg treatment response in CIDP.},
      cin          = {INM-3},
      ddc          = {610},
      cid          = {I:(DE-Juel1)INM-3-20090406},
      pnm          = {572 - (Dys-)function and Plasticity (POF3-572)},
      pid          = {G:(DE-HGF)POF3-572},
      typ          = {PUB:(DE-HGF)16},
      UT           = {WOS:000359354300001},
      pubmed       = {pmid:26268846},
      doi          = {10.1186/s12974-015-0361-1},
      url          = {https://juser.fz-juelich.de/record/203298},
}